Generate Biomedicines, Inc. GENB
10.38 USD +0.54 (+5.49%)
Regular-session close
10.40 +0.02 +0.19%
After hours · Nov 18, 5:21 PM ET
9.68 Day range 10.52
9.68 52-week range 22.67
- YTD
- -17.94%
- 1 year
- -17.94%
News
benzinga.com Morgan Stanley Maintains Overweight on Generate Biomedicines, Lowers Price Target to $21 Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.
benzinga.com Generate Biomedicines Q3 EPS $(0.68) Misses $(0.59) Estimate, Sales $4.220M Miss $7.750M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.59) by 15.25 percent. This is a 65.48 percent increase over…
globenewswire.com Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand…
globenewswire.com Generate Biomedicines to Participate in November Investor Conferences SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
defenseworld.net Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENB Banque Pictet and Cie SA purchased a new stake in Generate Biomedicines Inc (NASDAQ: GENB) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).…
globenewswire.com Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases…
globenewswire.com Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
seekingalpha.com Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two…
defenseworld.net Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB) Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
globenewswire.com Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical…
defenseworld.net Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB Squarepoint Ops LLC bought a new position in Generate Biomedicines Inc (NASDAQ: GENB) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
seekingalpha.com Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Generate Biomedicines Inc. to Participate in September Investor Conferences SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…
proactiveinvestors.com Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends…
proactiveinvestors.com Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO...
globenewswire.com Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be…
fool.com This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.
fool.com Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful…
prnewswire.com AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced…
fool.com A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
prnewswire.com Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday,…
prnewswire.com Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in…
